Transfer of Feces in Ulcerative Colitis 2

Prior treatment

• Use of topical therapy in preceding 2 weeks
• Vasopressive medication, icu stay

Other illness

• Condition leading to profound immunosuppression
  • For example: HIV, infectious diseases leading to immunosuppression, bone marrow malignancies
  • Use of systemic chemotherapy
  • Child-Pugh B liver cirrhosis
• Positive serological test for HIV
• History of surgery:
  • presence of a pouch
  • presence of stoma
• Known intra-abdominal fistula
• Allergy to macrogol or substituents, eg peanuts, shellfish
• Known allergy to iv gadolinium in the subgroup of patients who would be scheduled for MRI liver
• Crohn's disease
• Subject who has any conditions that in the opinion of the investigator, would compromise the safety of the subject or the quality of the data and is an unsuitable candidate for the study

Other

• Anti-TNFα treatment in preceding 2 months
• Vedolizumab treatment in preceding 2 months
• Tofacitinib treatment in preceding 2 months
• Ustekinumab treatment in preceding 2 months
• Cyclosporine treatment in preceding 4 weeks
• Use of Methotrexate in preceding 2 months
• Prednisolone dose \> 15 mg/day in preceding 2 weeks
• Life expectancy \< 12 months
• Difficulty with swallowing
• Use of systemic antibiotics in preceding 4 weeks
• Use of probiotic treatment in preceding 4 weeks
• Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli)
• Positive C. Difficile stool test
• Positive dual faeces test for pathogenic parasites e.g. Dientamoeba histolytica, Giardia Lamblia, Dientamoeba fragilis, Blastocystis hominis only if microscopically many or very many blastocysts are seen.
• Pregnancy or women who give breastfeeding
• Signs of ileus, diminished passage

• Age ≥18 and \<70
• Ability to give informed consent
• Established ulcerative colitis with known involvement of the left colon according to the Lennard-Jones criteria
• Partial mayo score of ≥ 3 and calprotectin \> 250
• Full Mayo score 5-9
• Endoscopic Mayo score of ≥2 in either the rectum or sigmoid upon screening sigmoidoscopy
• Stable dose of thiopurines or , 5-ASA, or budesonide in preceding 8 weeks.
• Stable dose of budesonide in preceding 2 weeks.
• Prednisone use ≤15mg/day in preceding 2 weeks with a mandatory taper of 5 mg per week starting from week 4.
• Women need to use reliable contraceptives during participation in the study
• Alkaline phosphatase \> 1.5 x ULN in the subgroup of PSC/UC patients.